TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03103334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeneo® - Methotrexate
Description: 0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeneo® - Methotrexate
Description: 0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeneo® - Methotrexate
Description: 0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeneo® - Methotrexate
Description: 0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Biodim®
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Biodim®
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Biodim®
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Biodim®
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
Study: NCT03429270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDOC 5Fr
Description: A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
Study: NCT03308370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: 10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
Study: NCT00409734

Intervention type: BEHAVIORAL
Intervention: Children with pyloric stenosis
Description: Both cohorts' feeding habits will be observed and recorded for the purposes of comparison

Intervention type: BEHAVIORAL
Intervention: Children without pyloric stenosis
Description: Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
Study: NCT02812862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiolto® Respimat® (Tiotropium / Olodaterol)
Description: LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent.
Study: NCT04084691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercice - moderate intensity
Description: standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercice - high intensity
Description: standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercice - workout
Description: standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal meal
Description: - Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normalized meal
Description: - Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: non meal in the hour before exercise
Study: NCT03646396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-daclatasvir
Description: Sofosbuvir-daclatasvir for 3 months
Study: NCT03775135

Intervention type: OTHER
Intervention: Questionnaires
Description: Different questionnaires about identity development and psychosocial functioning will be administered
Study: NCT02252796

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Boost
Description: An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Boost
Description: An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given during chemo-radiation phase and optional consolidative phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given during chemo-radiation phase and optional consolidative phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given during chemo-radiation phase and optional consolidative phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given during chemo-radiation phase and optional consolidative phase.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided IMRT
Description: Given during chemo-radiation phase

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided IMRT
Description: Given during chemo-radiation phase
Study: NCT03805282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Continuous infusion, variable dose of lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Continuous infusion, variable dose of lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Continuous infusion, variable dose of lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Continuous infusion, variable dose of lidocaine.
Study: NCT04306341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real time fMRI neurofeedback
Description: Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
Study: NCT02561832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: tablets taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injections on day one of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
Study: NCT03860493

Intervention type: PROCEDURE
Intervention: Perfusion evaluation with indocyanine green
Description: 1. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs.
Study: NCT03284580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention
Description: An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural plus kinesiotherapy intervention program
Description: An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Control or conservative intervention
Description: A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
Study: NCT00210951

Intervention type: OTHER
Intervention: No Intervention
Description: Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
Study: NCT00594815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
Description: Immunochemotherapy
Study: NCT04609462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy
Description: Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: Breathing support with High-flow nasal cannula
Study: NCT00742261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089
Description: Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
Study: NCT03481686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients with injections of ESA
Description: Patients will perform ASE injections themselves or by their spouses
Study: NCT04108637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: penicillin allergy assessment pathway
Description: Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction
Study: NCT02232568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Study: NCT00470275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT03656380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg
Description: Mepolizumab 300 mg subcutaneous injection

Intervention type: DRUG
Group type: OTHER
Intervention: Mepolizumab 100 mg
Description: Mepolizumab 100 mg subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline subcutaneous injection
Study: NCT04287270

Intervention type: OTHER
Group type: OTHER
Intervention: Assesment
Description: Evaluations which explained in the arms section will be made as described.
Study: NCT02829567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Study: NCT02519985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcScan Insight 100 very high-frequency digital ultrasound
Description: The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
Study: NCT02970903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalPAD
Description: VitalPAD prototype device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional tools
Description: Paper based records, screenshots of monitors and therapy devices
Study: NCT01551511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical step-up approach to the Namisol arm.
Study: NCT03715049

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fraxel Laser Treatment
Description: The device to be used in this study is a FDA approved device \[510(k) approval\] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
Study: NCT03993106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sEphB4-HSA
Description: sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
Study: NCT01168037

Intervention type: DEVICE
Intervention: Endovascular aortic repair with branched/fenestrated stent-graft
Description: Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram

Intervention type: DEVICE
Intervention: Endovascular aortic repair with branched/fenestrated stent-graft
Description: Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram

Intervention type: PROCEDURE
Intervention: Open Surgical Repair
Description: aortic replacement with revascularization of visceral arteries
Study: NCT06090136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: 5 mg TPN171H tablets，single dose,oral
Study: NCT00299390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
Study: NCT03916900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
Study: NCT03034070

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic performance 3D T1
Description: Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study.
Study: NCT01580215

Intervention type: DEVICE
Intervention: Zephyr Endobronchial Valve (EBV)
Description: • Implantation of at least one Zephyr EBV following Chartis assessment
Study: NCT05021068

Intervention type: OTHER
Intervention: Postural Assessment
Description: Spinal mouse measurement

Intervention type: OTHER
Intervention: Postural Assessment
Description: Spinal mouse measurement
Study: NCT02125669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: Pulsed dye laser 595nm

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM-Treatment
Description: using the pulsed dye laser (PDL) laser without releasing a pulse
Study: NCT00241189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study: NCT02625909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL for 6 weeks
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL for 12 weeks
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
Study: NCT03873792

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women
Description: Physician diagnoses a history of asthma or eczema or allergic rhinitis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women
Description: Physician diagnoses a history of asthma or eczema or allergic rhinitis
Study: NCT03739203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine supplied in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine supplied in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT as prescribed by the physician per standard of care in clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT as prescribed by the physician per standard of care in clinical practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant Therapy (ADT)
Description: ADT as prescribed by the physician per standard of care in clinical practice.
Study: NCT02367833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Contraceptive
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive Vaginal Ring
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
Study: NCT04276948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAD3
Description: NAD3 is an over-the-counter dietary supplement available online to consumers.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAD3
Description: NAD3 is an over-the-counter dietary supplement available online to consumers.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NAD3
Description: NAD3 is an over-the-counter dietary supplement available online to consumers.
Study: NCT02293317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-001
Description: A recombinant epitope based universal vaccine against seasonal and pandemic influenza

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-001
Description: A recombinant epitope based universal vaccine against seasonal and pandemic influenza

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIV
Description: HA based seasonal influenza vaccine, for 2014/15 seson

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIV
Description: HA based seasonal influenza vaccine, for 2014/15 seson

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TIV
Description: HA based seasonal influenza vaccine, for 2014/15 seson

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT02842489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left lateral tilt-down position
Description: patients will be positioned on their left side and at an angle of 20 degree

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: left lateral horizontal position
Description: patients will be horizontally positioned on their left side
Study: NCT04730232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.